CEVA Matrix Technology: A new alternative for pig medicated premixes

摘要

Specific problems are posed by medicated premixes : stability of the active ingredient, homogeneity of the medicated premix distribution in the feed and cross-contammation due to dust emission These problems can have two major consequences· a treatment failure and a risk for human health with selection of res1stant strains CEVA Matrix Technology, an exclusive CEVA Sante Ammale manufacturing process, matches all expectations of an effective and modern medicated premix. CEVA Matrix Technology consists of an innovative protective granulation technology. Most non-protected medicated premixes available in the market do not provide good stability and may not reach efficient concentration as the active ingredient is not protected enough. First, the CEVA Matrix Technology guarantees that the active ingredient is protected during manufacture (pelleting) and storage of the medicated feed without altenng its bioavailability. Secondly, the particle size of CEVA Matrix Technology premixes is similar to the feed in which it is to be blended. Therefore the active ingredient is mixed homogeneously into the feed and remains homogeneous even after transportation and storage. This perfect mixability ensures the right active ingredient concentration and dosage in feed every time. Consequently, treatment failure resulting from unequal dosage distribution of the active ingredient in the feed is considerably limited. Thirdly, CEVA Matrix Technology guarantees that the premix does not release dust. Therefore, it reduces risks such as cross contamination between two medicated feed batches in mills and inhalation of antimicrobial by users. It protects the workforce and reduces the risk of selecting resistant strams. This article validates all these points by comparing a tiamulin medicated premix manufactured with the CEVA Matrix Technology and some non-protected tiamulin.